Please assess the completion status of the following clinical trial:

Trial Title: SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed grade III cervical intraepithelial neoplasia (CIN III) with colposcopically visible cervical lesions~* No positive endocervical curettage or inadequate colposcopy at the time of initial cervical biopsy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* WBC at least 3,500/mm\^3~* Lymphocyte count at least 500/mm\^3~* Platelet count at least 150,000/mm\^3~* Hemoglobin at least 10 g/dL~* No significant hematologic disease that is uncontrolled with standard therapy~Hepatic~* Bilirubin no greater than 2 mg/dL~* Liver enzymes no greater than 2.5 times normal~* No significant hepatic disease that is uncontrolled with standard therapy~Renal~* Creatinine no greater than 2 mg/dL~* No significant renal disease that is uncontrolled with standard therapy~Cardiovascular~* No significant cardiovascular disease that is uncontrolled with standard therapy~Pulmonary~* No significant respiratory disease that is uncontrolled with standard therapy~* No history of asthma~Immunologic~* HIV negative~* No clinical evidence of immunosuppression~* No autoimmune disease~* No history of allergic reactions attributed to compounds of similar chemical or biological activity as those used in this study~* No history of a positive purified protein derivative (PPD) or Tine test~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Good health based upon the results of a medical history, physical examination, vital signs, and laboratory profile~* No uncontrolled chronic disease~  * Chronic disease requiring medication is allowed provided the patient is not taking immunosuppressive drugs~* No significant endocrine (e.g., thyroid or diabetes), neurologic, gastrointestinal, or dermatologic disease that is uncontrolled with standard therapy~* No other underlying or unstable disease that would be exacerbated by the study treatment~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior BCG vaccination~* No other concurrent vaccine therapy~Chemotherapy~* No concurrent chemotherapy~Endocrine therapy~* More than 30 days since prior oral or parenteral glucocorticoid steroid~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* More than 30 days since prior participation in another investigational study~* No concurrent cytotoxic therapy~* No other concurrent investigational agents~* No other concurrent investigational or commercial agents or therapies intended to treat CIN

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- 1 month follow-up (Type: ACTIVE_COMPARATOR): 3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
- 2 month follow-up (Type: ACTIVE_COMPARATOR): 3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).